These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28414564)

  • 1. Tivantinib for the treatment of hepatocellular carcinoma.
    Best J; Schotten C; Lohmann G; Gerken G; Dechêne A
    Expert Opin Pharmacother; 2017 May; 18(7):727-733. PubMed ID: 28414564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
    Rimassa L; Santoro A; Daniele B; Germano D; Gasbarrini A; Salvagni S; Masi G; Abbadessa G; Lamar M; Goldberg T; Porta C
    Tumori; 2015; 101(2):139-43. PubMed ID: 25838254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
    Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
    Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Woo HY; Yoo SY; Heo J
    Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
    Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
    Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
    Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
    Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.
    Qi XS; Guo XZ; Han GH; Li HY; Chen J
    World J Gastroenterol; 2015 May; 21(18):5445-53. PubMed ID: 25987766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
    Kobayashi K; Higai K; Mukozu T; Matsui D; Amanuma M; Yoshimine N; Ogino Y; Matsui T; Wakui N; Shinohara M; Momiyama K; Daido Y; Nagai H; Igarashi Y
    Biol Pharm Bull; 2020; 43(9):1421-1425. PubMed ID: 32879217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.
    Rimassa L; Personeni N; Simonelli M; Santoro A
    Future Oncol; 2013 Feb; 9(2):153-65. PubMed ID: 23414466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
    Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
    Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.